Tenaya Therapeutics is trading 5.36% down at $0.58 amid broader market pressure; no clear company-specific announcement explaining the September 28 decline surfaced.
- Its latest identified company news was the September 14 FDA RMAT designation for TN-401.
- Reuters reported U.S. futures fell after President Trump rejected Iran’s proposal, lifting oil prices and reigniting inflation concerns as Treasury yields rose.
- The provided market context also shows major U.S. indexes down, consistent with broader pressure rather than a confirmed company-specific catalyst.